Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation

DUBLIN, Nov. 11, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to the research and development of new treatments for gastrointestinal diseases, today announced that new data from its nonalcoholic steatohepatitis (NASH) portfolio will be featured in poster presentations and an oral plenary session at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, MA, November 11-15, 2016.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO 

The scheduled times of the presentations at the John B. Hynes Veterans Memorial Convention Center are as follows:

• Effect of Cenicriviroc on the Pharmacokinetics and Safety of HMG-CoA Reductase Inhibitors (Atorvastatin, Simvastatin and Rosuvastatin) in Healthy Subjects  
  Date and Time: Saturday, November 12, 5:30-7:00pm ET  
  Poster Session II/1112
• Cenicriviroc versus placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study  
  Date and Time: Monday, November 14, 3:00-4:30pm ET  
  Late Breaking Oral Session

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Investors:  
Lisa DeFrancesco   
(862) 261-7152

Media:  
Mark Marmur
(862) 261-7558

Fran DeSena  
(973) 517-3132

SOURCE Allergan plc

Related Links

http://www.allergan.com